AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38346403 — intervention group
Group type: EXPERIMENTAL
Intervention: Single relationship status and increased number of recent sexual partners
Number of subjects: 432
Study 38346438 — intervention group
Group type: EXPERIMENTAL
Intervention: mtFIT
Number of subjects: 13187
Study 38346438 — intervention group
Group type: COMPARATOR
Intervention: FIT
Number of subjects: 13187
Study 38346438 — intervention group
Group type: EXPERIMENTAL
Intervention: mtFIT-based screening
Number of subjects: 13187
Study 38346442 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy plus medical care
Number of subjects: 352
Study 38346442 — intervention group
Group type: COMPARATOR
Intervention: Medical care alone
Number of subjects: 352
Study 38346785 — intervention group
Group type: EXPERIMENTAL
Intervention: ticagrelor-ASA
Number of subjects: 5440
Study 38346785 — intervention group
Group type: COMPARATOR
Intervention: clopidogrel-ASA
Number of subjects: 5440
Study 38346874 — intervention group
Group type: EXPERIMENTAL
Intervention: qER EU 2.0 AI tool
Number of subjects: 30
Study 38346874 — intervention group
Group type: COMPARATOR
Intervention: No AI assistance (control)
Number of subjects: 30
Study 38346877 — intervention group
Group type: EXPERIMENTAL
Intervention: CR standard care+mHealth supported exercise counselling
Number of subjects: 0
Study 38346877 — intervention group
Group type: COMPARATOR
Intervention: CR standard care
Number of subjects: 0
Study 38346879 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Allostatic Load (AL) index
Number of subjects: 106808
Study 38346879 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Mean AL index
Number of subjects: 106808
Study 38347150 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDiet intervention (anti-inflammatory diet) for 12 weeks, without energy deficit.
Number of subjects: 32
Study 38347177 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor combined with albumin paclitaxel and apatinib
Number of subjects: 43
Study 38347192 — intervention group
Group type: EXPERIMENTAL
Intervention: FODMAPs
Number of subjects: 0
Study 38347192 — intervention group
Group type: EXPERIMENTAL
Intervention: gluten
Number of subjects: 0
Study 38347192 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 38347302 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus modified FOLFOX6
Number of subjects: 733
Study 38347302 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus modified FOLFOX6
Number of subjects: 733
Study 38347302 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 733
Study 38347458 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo PET of synaptic density
Number of subjects: 110
Study 38347499 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity coach (mHealth tool)
Number of subjects: 9
Study 38347550 — intervention group
Group type: EXPERIMENTAL
Intervention: REBOA-CPR (Resuscitative Endovascular Balloon Occlusion of the Aorta with standard advanced cardiovascular life support)
Number of subjects: 0
Study 38347550 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPR (based on the 2020 American Heart Association guidelines)
Number of subjects: 0
Study 38347552 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular tumor board (MTB) recommended combination therapy
Number of subjects: 186
Study 38347557 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable smartwatches collecting heart rate, step count, and sleep data; online baseline and quarterly surveys.
Number of subjects: 360
Study 38347557 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine administrative systems-level data on nursing care outcomes abstracted weekly.
Number of subjects: 360
Study 38347614 — intervention group
Group type: EXPERIMENTAL
Intervention: IV iron treatment
Number of subjects: 140
Study 38347736 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy (DC) plus best medical treatment (BMT)
Number of subjects: 300
Study 38347736 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (BMT) alone
Number of subjects: 300
Study 38347747 — intervention group
Group type: EXPERIMENTAL
Intervention: Elranatamab
Number of subjects: 0
Study 38347747 — intervention group
Group type: COMPARATOR
Intervention: Teclistamab
Number of subjects: 0
Study 38347908 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 350
Study 38347908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 38348238 — intervention group
Group type: EXPERIMENTAL
Intervention: macitentan 10 mg, with or without a phosphodiesterase 5 inhibitor (PDE5i)
Number of subjects: 0
Study 38348246 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients (GOLD 3-4)
Number of subjects: 3183
Study 38348246 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients (GOLD 1-2, pre-COPD, PRISm)
Number of subjects: 3183
Study 38348246 — intervention group
Group type: EXPERIMENTAL
Intervention: pre-COPD and GOLD 1-2
Number of subjects: 3183
Study 38348246 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISm and GOLD 3-4
Number of subjects: 3183
Study 38348246 — intervention group
Group type: EXPERIMENTAL
Intervention: pre-COPD
Number of subjects: 3183
Study 38348246 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD 1-2 and PRISm
Number of subjects: 3183
Study 38348309 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex interdisciplinary lifestyle and psychosocial intervention
Number of subjects: 211
Study 38348309 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 211
Study 38348498 — intervention group
Group type: EXPERIMENTAL
Intervention: High sun exposure
Number of subjects: 407
Study 38348498 — intervention group
Group type: EXPERIMENTAL
Intervention: A allele of VDR polymorphism Fok1
Number of subjects: 407
Study 38348498 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of mitosis in primary tumor
Number of subjects: 407
Study 38348498 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural invasion in primary tumor
Number of subjects: 407
Study 38348651 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG glycan score derived from selected IgG N-glycans in JUPITER
Number of subjects: 559
Study 38348651 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG glycan score validated in TNT
Number of subjects: 559
Study 38348651 — intervention group
Group type: EXPERIMENTAL
Intervention: Model with IgG glycan score in JUPITER
Number of subjects: 559
Study 38348651 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalactosylated glycan (IgG-GP4)
Number of subjects: 559
Study 38348651 — intervention group
Group type: EXPERIMENTAL
Intervention: Three digalactosylated glycans (IgG glycan peaks 12, 13, 14)
Number of subjects: 559
Study 38348651 — intervention group
Group type: EXPERIMENTAL
Intervention: Two monosialylated glycans (IgG glycan peaks 18, 20)
Number of subjects: 559
Study 38348677 — intervention group
Group type: EXPERIMENTAL
Intervention: DCB followed by provisional bare metal stenting
Number of subjects: 1397
Study 38348677 — intervention group
Group type: COMPARATOR
Intervention: DCB alone
Number of subjects: 1397
Study 38348690 — intervention group
Group type: EXPERIMENTAL
Intervention: Zenocutuzumab, dosage and duration not specified
Number of subjects: 0
Study 38348778 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 48
Study 38348778 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care
Number of subjects: 48
Study 38348805 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged <45 years with Takotsubo Syndrome
Number of subjects: 2492
Study 38348805 — intervention group
Group type: COMPARATOR
Intervention: Patients aged 45-64 years with Takotsubo Syndrome
Number of subjects: 2492
Study 38348805 — intervention group
Group type: COMPARATOR
Intervention: Patients aged 65-74 years with Takotsubo Syndrome
Number of subjects: 2492
Study 38348805 — intervention group
Group type: COMPARATOR
Intervention: Patients aged ≥75 years with Takotsubo Syndrome
Number of subjects: 2492
Study 38348815 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency HRV
Number of subjects: 94
Study 38348815 — intervention group
Group type: EXPERIMENTAL
Intervention: Parasympathetic measures of HRV
Number of subjects: 94
Study 38348827 — intervention group
Group type: EXPERIMENTAL
Intervention: Social interventions for support during treatment for endometrial cancer
Number of subjects: 0
Study 38348827 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38348848 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV reactivation (defined as HBsAg reappearance or HBV DNA reappearance or greater than 10-fold increase above baseline)
Number of subjects: 462
Study 38348848 — intervention group
Group type: COMPARATOR
Intervention: No HBV reactivation
Number of subjects: 462
Study 38348930 — intervention group
Group type: EXPERIMENTAL
Intervention: Early developmental interventions
Number of subjects: 5051
Study 38348944 — intervention group
Group type: EXPERIMENTAL
Intervention: High Pain at 3 months
Number of subjects: 718
Study 38348944 — intervention group
Group type: EXPERIMENTAL
Intervention: High Pain at 12 months
Number of subjects: 718
Study 38349205 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model based on preoperative CT images (DL-score)
Number of subjects: 405
Study 38349205 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning radiomics nomogram (DLRN)
Number of subjects: 405
Study 38349205 — intervention group
Group type: COMPARATOR
Intervention: Classic handcrafted radiomics model (Rad-score)
Number of subjects: 405
Study 38349205 — intervention group
Group type: COMPARATOR
Intervention: Clinical model
Number of subjects: 405
Study 38349219 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical alignment during TKA
Number of subjects: 353
Study 38349219 — intervention group
Group type: COMPARATOR
Intervention: Restricted kinematic alignment during TKA
Number of subjects: 353
Study 38349226 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)
Number of subjects: 519
Study 38349241 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time fMRI neurofeedback (15 weekly sessions)
Number of subjects: 43
Study 38349241 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT) (10 weekly group sessions)
Number of subjects: 43
Study 38349333 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 × 10^7 HXTCs/m² with VOR 400 mg
Number of subjects: 9
Study 38349333 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 × 10^7 HXTCs/m² with VOR
Number of subjects: 9
Study 38349333 — intervention group
Group type: EXPERIMENTAL
Intervention: VOR and HXTCs
Number of subjects: 9
Study 38349371 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin (single-dose treatment twice yearly for 3 years, 6 distributions)
Number of subjects: 68346
Study 38349371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68346
Study 38349471 — intervention group
Group type: EXPERIMENTAL
Intervention: 50g Prune
Number of subjects: 235
Study 38349471 — intervention group
Group type: EXPERIMENTAL
Intervention: 100g Prune
Number of subjects: 235
Study 38349471 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 235
Study 38349570 — intervention group
Group type: EXPERIMENTAL
Intervention: Feladilimab in combination with tremelimumab (24/225 mg)
Number of subjects: 26
Study 38349570 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 26
Study 38349618 — intervention group
Group type: EXPERIMENTAL
Intervention: CT‑P41 (60-mg subcutaneous dose)
Number of subjects: 154
Study 38349618 — intervention group
Group type: COMPARATOR
Intervention: US-denosumab (60-mg subcutaneous dose)
Number of subjects: 154
Study 38349655 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline catheters (MCs)
Number of subjects: 304
Study 38349655 — intervention group
Group type: COMPARATOR
Intervention: Peripherally inserted central catheters (PICCs)
Number of subjects: 304
Study 38349712 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Care Program (educational videos and follow-up visits by a family medicine physician)
Number of subjects: 350
Study 38349712 — intervention group
Group type: COMPARATOR
Intervention: Routine care and intervention (control group)
Number of subjects: 350
Study 38349721 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based Culinary Medicine intervention group (CMG) received weekly cooking demonstrations and biweekly nutrition education videos.
Number of subjects: 47
Study 38349721 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) received only recipe handouts.
Number of subjects: 47
Study 38349734 — intervention group
Group type: EXPERIMENTAL
Intervention: MARVIN chatbot intervention for HIV
Number of subjects: 180
Study 38349734 — intervention group
Group type: EXPERIMENTAL
Intervention: MARVIN chatbot intervention for breast cancer
Number of subjects: 180
Study 38349734 — intervention group
Group type: EXPERIMENTAL
Intervention: MARVIN-Pharma for community pharmacists providing HIV care
Number of subjects: 180
Study 38349734 — intervention group
Group type: EXPERIMENTAL
Intervention: MARVIN-CHAMP for pediatric infectious conditions
Number of subjects: 180
Study 38349734 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based questionnaires for usability, acceptability, and appropriateness
Number of subjects: 180
Study 38349737 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples HIV testing and counseling (CHTC) retesting
Number of subjects: 106
Study 38349737 — intervention group
Group type: COMPARATOR
Intervention: Individual HIV testing
Number of subjects: 106
Study 38349899 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of mono- and diglycerides of fatty acids (E471)
Number of subjects: 92000
Study 38349899 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of total carrageenans (E407 and E407a)
Number of subjects: 92000
Study 38349899 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of carrageenan (E407)
Number of subjects: 92000
Study 38349899 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsifiers
Number of subjects: 92000
Study 38349910 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloth facemasks distributed to intervention clusters (n = 90)
Number of subjects: 39574
Study 38349910 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 91) received facemasks later
Number of subjects: 39574
Study 38349951 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 meals + 3 snacks/day
Number of subjects: 40
Study 38349951 — intervention group
Group type: COMPARATOR
Intervention: 2 meals/day
Number of subjects: 40
Study 38350047 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy after nephroureterectomy
Number of subjects: 0
Study 38350047 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant chemotherapy)
Number of subjects: 0
Study 38350126 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous catheter change
Number of subjects: 0
Study 38350126 — intervention group
Group type: COMPARATOR
Intervention: Closed-loop mode
Number of subjects: 0
Study 38350126 — intervention group
Group type: COMPARATOR
Intervention: Open-loop mode
Number of subjects: 0
Study 38350161 — intervention group
Group type: EXPERIMENTAL
Intervention: EVO-Visian ICL V4c (VICMO) implantation
Number of subjects: 95
Study 38350194 — intervention group
Group type: EXPERIMENTAL
Intervention: Customised 3D-printed insoles (ZOLES)
Number of subjects: 200
Study 38350194 — intervention group
Group type: COMPARATOR
Intervention: Do-as-usual control group
Number of subjects: 200
Study 38350221 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (TBS) to dorsomedial prefrontal cortex (dmPFC)
Number of subjects: 29
Study 38350342 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted mobilization
Number of subjects: 23
Study 38350465 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic (MSP) supplementation (4 × 10^9 live cells of Limosilactobacillus fermentum LF16, Lacticaseibacillus rhamnosus LR06, Lactiplantibacillus plantarum LP01, and Bifidobacterium longum 04)
Number of subjects: 70
Study 38350465 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 70
Study 38350465 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic (MSP) supplementation
Number of subjects: 70
Study 38350481 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic-amylase blend (PRO)
Number of subjects: 60
Study 38350481 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 60
Study 38350486 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (SynForU-HerCare)
Number of subjects: 78
Study 38350486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 38350494 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-rate aerobic exercise (FE) intervention
Number of subjects: 60
Study 38350494 — intervention group
Group type: COMPARATOR
Intervention: Upper extremity repetitive task practice (UE RTP) control group
Number of subjects: 60
Study 38350507 — intervention group
Group type: EXPERIMENTAL
Intervention: BP sirolimus-eluting FIREHAWK stent (SES)
Number of subjects: 1653
Study 38350507 — intervention group
Group type: COMPARATOR
Intervention: DP everolimus-eluting XIENCE stent (EES)
Number of subjects: 1653
Study 38350600 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS (digital therapeutic with 11 tailored modules plus five thirty-minute therapist support sessions)
Number of subjects: 194
Study 38350600 — intervention group
Group type: COMPARATOR
Intervention: Standard charity support (SCS)
Number of subjects: 194
Study 38350670 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG and OPV vaccination provided at home visit within 72 hours after birth
Number of subjects: 2226
Study 38350670 — intervention group
Group type: COMPARATOR
Intervention: Control group (no early BCG and OPV vaccination)
Number of subjects: 2226
Study 38350670 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG and OPV vaccination
Number of subjects: 2226
Study 38350854 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 50
Study 38350888 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of systemic therapy with total ablative therapy (TAT) including surgical resection, microwave ablation, and/or stereotactic ablative body radiotherapy (SABR) for at least one lesion.
Number of subjects: 346
Study 38350888 — intervention group
Group type: COMPARATOR
Intervention: Continuation of systemic therapy without total ablative therapy (TAT).
Number of subjects: 346
Study 38350888 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary endpoints include event-free survival, adverse events profile, and time to local recurrence with exploratory biomarker analyses.
Number of subjects: 346
Study 38350937 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of the ear point with alleged parasympathetic activity
Number of subjects: 10
Study 38350937 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of the ear point with alleged sympathetic activity
Number of subjects: 10
Study 38350937 — intervention group
Group type: COMPARATOR
Intervention: Cold water immersion
Number of subjects: 10
Study 38350937 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of two different ear points
Number of subjects: 10
Study 38351039 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroTest® stages
Number of subjects: 617
Study 38351039 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroTest® score
Number of subjects: 617
Study 38351039 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroTest® F3-F4 stage
Number of subjects: 617
Study 38351146 — intervention group
Group type: EXPERIMENTAL
Intervention: lurbinectedin
Number of subjects: 0
Study 38351182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 27
Study 38351182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab/ipilimumab
Number of subjects: 27
Study 38351182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab/radiation therapy
Number of subjects: 27
Study 38351182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab/ipilimumab with concurrent radiotherapy
Number of subjects: 27
Study 38351187 — intervention group
Group type: EXPERIMENTAL
Intervention: durvalumab-ceralasertib
Number of subjects: 268
Study 38351187 — intervention group
Group type: COMPARATOR
Intervention: Other regimens (pooled)
Number of subjects: 268
Study 38351187 — intervention group
Group type: EXPERIMENTAL
Intervention: durvalumab-ceralasertib in ATM-altered patients
Number of subjects: 268
Study 38351528 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer supportive care needs assessment
Number of subjects: 47
Study 38351528 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment using the Functional Assessment of Cancer Therapy
Number of subjects: 47
Study 38352207 — intervention group
Group type: EXPERIMENTAL
Intervention: Onion Peel Extract (OPE) 1,000 mg/day for 8 weeks
Number of subjects: 80
Study 38352207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 38352390 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm with subsidized mRDT testing and free ACT for positive tests; PMRs received USD $0.2 for every mRDT performed.
Number of subjects: 0
Study 38352390 — intervention group
Group type: COMPARATOR
Intervention: Control arm offering subsidized mRDT testing for USD $0.66.
Number of subjects: 0
Study 38352524 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital anal rectal examinations (DARE)
Number of subjects: 838
Study 38353018 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for PHCI
Number of subjects: 64
Study 38353022 — intervention group
Group type: EXPERIMENTAL
Intervention: NASH (non-alcoholic steatohepatitis)
Number of subjects: 113
Study 38353022 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe fibrosis (F3-F4)
Number of subjects: 113
Study 38353022 — intervention group
Group type: COMPARATOR
Intervention: NASH vs NLO
Number of subjects: 113
Study 38353022 — intervention group
Group type: COMPARATOR
Intervention: Severe fibrosis (F3-F4) vs F0
Number of subjects: 113
Study 38353060 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 48
Study 38353060 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed rehabilitation (initial loading delayed by 6 weeks)
Number of subjects: 48
Study 38353060 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed rehabilitation
Number of subjects: 48